Supernus Pharmaceuticals Total Revenue

Supernus Pharmaceuticals (SUPN) currently reports a total revenue of $190B as of June 2026. That compares with $670M in the prior-year period — up 28878.2% year over year. That is above the Healthcare sector average of $110B. Use the charts on this page to explore Supernus Pharmaceuticals's total revenue history and peer comparisons.

Supernus Pharmaceuticals's total revenue increased from $670M to $190B — a 28878.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Supernus Pharmaceuticals's total revenue of $190B is higher than the Healthcare sector average of $110B. That is roughly 76.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Supernus Pharmaceuticals reported $190B in total revenue as of June 2026. That compares with $670M in the prior-year period — up 28878.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $190B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Supernus Pharmaceuticals, and consider following SUPN for alerts when major investors trade the stock.